Safety surveillance of esterified estrogens—methyltestosterone (Estratest® and Estratest® HS) replacement therapy in the United States
- 31 October 1997
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 19 (5) , 1070-1084
- https://doi.org/10.1016/s0149-2918(97)80060-4
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal MenNew England Journal of Medicine, 1996
- Androgens in Men — Uses and AbusesNew England Journal of Medicine, 1996
- Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal womenJournal of Clinical Endocrinology & Metabolism, 1996
- The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 1995
- Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopauseObstetrics & Gynecology, 1995
- Hormone replacement therapy and endometrial cancer risk: A meta-analysisObstetrics & Gynecology, 1995
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Hepatotoxic Effects of the Anabolic/Androgenic SteroidsSeminars in Liver Disease, 1987
- Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic ProblemsObstetrics & Gynecology, 1979
- The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research GroupPublished by American Medical Association (AMA) ,1973